MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Molecular Interventions 5:163-171, (2005)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.5.3.6
This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peng, X.
Right arrow Articles by Sawyer, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peng, X.
Right arrow Articles by Sawyer, D. B.
Review

The Cardiotoxicology of Anthracycline Chemotherapeutics: TRANSLATING MOLECULAR MECHANISM INTO PREVENTATIVE MEDICINE

Xuyang Peng, Billy Chen, Chee Chew Lim and Douglas B. Sawyer

Whitaker Cardiovascular Institute and Center for Molecular Stress Response, Boston University Medical Center, 650 Albany Street, Boston, MA 02118


{Sawyer_Titleart}


   SUMMARY
TOP
 Summary
Introduction
 Overview of Anthracycline...
 Mechanisms of Anthracycline...
 Designing Cardioprotective...
 References
 
Anthracyclines remain a mainstay of chemotherapy in spite of their well-recognized cardiotoxicity. Recent experience with trastuzumab (Herceptin) and anthracycline therapy has prompted a detailed analysis of the function of erbB2 in the heart. These studies demonstrate a cardioprotective effect of neuregulin, the endogenous ligand for the erbB4/erbB2 heterodimeric receptor complex. Although the mechanisms of cytoprotection remain incompletely understood, these studies have triggered the question of whether physiological manipulation of cardioprotective pathways that involve erbB can be used to improve outcome in patients treated with anthracyclines. The local activation of cardioprotection by cardiovascular exercise may be such a manipulation and warrants further investigation.


   INTRODUCTION
TOP
 Summary
 Introduction
Overview of Anthracycline...
 Mechanisms of Anthracycline...
 Designing Cardioprotective...
 References
 
Anthracycline antibiotics such as doxorubicin (i.e., adriamycin) and daunorubicin are some of the most effective chemotherapeutic agents used in the treatment of cancer; however, the utility of these pharmaceuticals is limited by cumulative, dose-related, progressive myocardial damage that may lead to congestive heart failure (CHF). Thus, the oncologist prescribing anthracyclines must constantly weigh the beneficial (i.e., anticancer) effects of the drug against the risk of cardiac toxicity. Much has been learned about the mechanisms of anthracycline cardiotoxicity since its first recognition. In spite of this knowledge, an acceptable strategy for prevention of anthracycline-induced cardiac toxicity, other than limitation of anthracycline exposure, remains lacking. Physicians treating patients whose tumors are responding to anthracyclines are often faced with the difficult question as to whether the risk of heart failure outweighs the benefits of further cancer therapy. As the incidence of cancer rises, so too does the incidence of anthracyclineinduced heart failure, which currently represents ~1% of patients with advanced heart failure due to ventricular systolic dysfunction. Recently, a novel drug targeting the erbB2 oncogene has been shown to increase the risk of anthracycline cardiotoxicity. This observation, together with work in animal and cell models, sheds new insight on how anthracycline toxicity is modulated by endogenous cardiac growth and survival signaling pathways. These observations lead to the hypothesis that physiological activation of these endogenous factors may yield clinically useful strategies for cardioprotection against this predictable cardiac insult.


   OVERVIEW OF ANTHRACYCLINE CARDIOTOXICITY
TOP
 Summary
 Introduction
 Overview of Anthracycline...
Mechanisms of Anthracycline...
 Designing Cardioprotective...
 References
 
Anthracycline antibiotics represent a major class of antitumor drugs and have been used in chemotherapy for over thirty years. They are highly effective and widely used in the treatment of leukemias, lymphomas, and adenocarcinomas. The mechanisms of cytotoxicity of anthracyclines in cancer cells include: 1) intercalation in DNA, leading to inhibition of both DNA replication and RNA transcription; 2) generation of free radicals, leading to DNA damage or lipid peroxidation; 3) DNA binding and alkylation; 4) DNA cross-linking; 5) interference with DNA unwinding, DNA strand separation, and helicase activity; 6) direct membrane damage due to lipid oxidation; and 7) inhibition of topoisomerase II. In response to some or all of these effects, tumor cell growth is inhibited and cells are more likely to die by one or more mechanisms. [For review, see (1).]

A major limitation of anthracycline use is a cumulative dosedependent cardiac toxicity (2) (Figure 1Go). Early strategies to prevent cardiac toxicity included reductions in single doses of anthracyclines, as well as prolonging the infusion of drug to limit peak serum concentrations. Despite these efforts, the cardiotoxicity remains. A large-scale study of 630 patients randomized to a doxorubicinplus- placebo arm of three phase III studies, over the years of 1988 to 1992, reported a 5.1% risk of congestive heart failure in patients receiving cumulative doses up to 400 mg/m2, rising to 48% in patients receiving doses up to 700 mg/m2. Congestive heart failure was reported in patients receiving as little as 300 mg/m2. Advanced age remains a significant risk factor, with patients older than sixtyfive years having triple the risk of doxorubicin-related CHF compared with younger patients at the same cumulative dose (3).



View larger version (17K):
[in this window]
[in a new window]
  		Figure 1. The cytotoxicity of anthracycline antibiotics occurs in normal tissues as well as the tumor target, and the effects on the heart pose a major clinical dilemma.

 
Anthracyclines have long been thought to induce cardiotoxicity by mechanisms other than those mediating their antitumor effectiveness, a concept that raises hope for the development of strategies that protect the heart without diminishing tumor response (2). Multiple proposed mechanisms of anthracycline-induced cardiac cellular injury have been based upon studies in animals and cell cultures, although it remains unclear which of these is at work in the clinical context of anthracycline use. Most mechanisms propose the induction of oxidative stress by the anthracyclines, but it is not clear why this would result in preferential cardiotoxicity. Anthracyclines induce membrane damage via lipid peroxidation in all tissues, including the heart (4, 5). Whereas formation of reactive oxygen species are induced by the quinone moiety of anthracyclines, oxidative stress can also occur via induction of nitric oxide synthase, leading to nitric oxide and peroxynitrite formation. This latter mechanism has been linked to nitration and inactivation of key enzymes in the heart including myofibrillar creatine kinase (6). Anthracyclines also cause impairment of membrane binding, assembly, and enzymatic activity of mitochondrial creatine kinase, although the consequences of this impairment are yet unclear (7). In the heart, like other tissue, anthracyclines intercalate into nucleic acids, causing suppression of DNA, RNA, and protein synthesis (8). Some transcriptional regulatory proteins that appear important for regulation of cardiac specific genes appear particularly susceptible to anthracyclines (9–11). This leads to impaired synthesis of myofilament proteins, which in the presence of accelerated myofilament degradation (12) creates a net negative balance of sarcomeric proteins, a "cardiac sarcopenia" (Figure 2Go). Myocyte cell death by both apoptosis and necrosis has also been implicated, and the net loss of cells may contribute to "cardiac wasting." Finally, anthracyclines induce changes in adrenergic function and adenylate cyclase (13–15) and abnormalities in Ca2+ handling (16), all critical for the dynamic regulation of cardiac function. The extent to which each of these contributes to dosedependent heart failure in anthracycline-treated patients remains controversial.



View larger version (18K):
[in this window]
[in a new window]
  		Figure 2. Mechanistic role of titin and anthracycline-induced cardiotoxicity. Myofilament damage is a key element in anthracycline-induced cardiotoxicity, which along with reduced myofilament protein synthesis contributes to the cardiac injury that begets heart failure. Specifically, treatment of myocytes with doxorubicin induces breakdown of the giant myofilament protein titin (185 kDa), ultimately leading to myofibrillar disarray and myocyte cell death. Titin normally spans the half sarcomere from M-line to Z-line and functions as a spring, storing the energy during systole and diastole that helps restore the cell to resting length (see inset). Hence, titin is essential to cardiac function, and its degradation alters myocyte contractile function in several ways that could contribute to the clinical syndrome of heart failure.

 
At present, there is no generally accepted method to provide selective protection of the heart from damage induced by anthracyclines. Modifications in dosing schedule and administration of anthracyclines can make a significant impact on the incidence of heart failure, whereas modification of anthracycline structure can result in compounds with reduced cardiotoxicity and allow for higher dose administration (17). Co-administration of anthracyclines with antioxidants has been tried with limited success; the cardioprotective efficacy of antioxidants like vitamin E or N-acetylcysteine is only limited in large-sized animals such as dogs or pigs. Similarly, clinical studies fail to document mitigation of cardiomyopathy in patients given robust doses of vitamin E or N-acetylcysteine (18, 19). The iron chelator dexrazoxane reduces the incidence of contractile dysfunction in cancer victims treated with anthracyclines (20); however, the possibility that dexrazoxane reduces tumor response rates has prevented its universal employment (21). Current guidelines from the American Society of Clinical Oncology support the use of dexrazoxane in the patients who have received high doses of doxorubicin (over 300 mg/m2) during certain treatment regimes (22). Hence, in spite of the significant efforts to understand and prevent anthracycline-induced cardiotoxicity, there is no universally accepted strategy.


   MECHANISMS OF ANTHRACYCLINE TOXICITY: INSIGHTS FROM HERCEPTIN THERAPY
TOP
 Summary
 Introduction
 Overview of Anthracycline...
 Mechanisms of Anthracycline...
Designing Cardioprotective...
 References
 
Newer cancer therapeutics have been developed that target specific oncogene products involved in regulation of cancer growth. One of these therapeutics, trastuzumab (Herceptin), appears to increase the susceptibility of the heart to anthracyclines, and this experience provides some new insight into the mechanisms of anthracycline cardiotoxicity. Trastuzumab targets the erbB2 (HER2/neu) oncogene product, a receptor tyrosine kinase in the four-member erbB family that comprises erbB1 (i.e., EGFR), erbB2, erbB3, and erbB4. erbB2 is a non–ligand-binding 185-kD transmembrane protein with a cytoplasmic tyrosine kinase domain that is normally activated by heterodimerization with erbB1, erbB3, or erbB4 (23). ErbB2 is overexpressed in 25–30% of human breast cancers, and this overexpression is associated with enhanced tumor aggressiveness and a poor prognosis (24). Several monoclonal antibodies have been developed against the HER2 ectodomain to specifically inhibit the growth of tumor cell lines overexpressing HER2. One monoclonal antibody, 4D5 (25), was fully cloned, and the Fc portion was "humanized" to create trastuzumab (Herceptin) (26). Trastuzumab antitumor activity against HER2-positive human breast tumor cells in laboratory models led to clinical trials that ultimately demonstrated a clinical benefit in women with HER2-overexpressing breast cancers (27). On the basis of trastuzumab clinical efficacy, this antibody was approved in 1998 for treatment of patients with HER2-overexpressing metastatic breast cancer.

Significantly, a fraction of patients treated with trastuzumab develop clinical heart failure with a decrease in cardiac contractile function (28). This development was most notable in patients who concurrently received anthracyclines (Figure 3Go); the incidence of cardiac dysfunction or symptomatic heart failure was about four times more likely in patients who received both trastuzumab and chemotherapeutic than in those who received anthracycline and cyclophosphamide alone. Although there was initial concern that the effect of trastuzumab on the heart would limit its use (29), more recent clinical trials have demonstrated lower rates of treatment-associated heart failure. Moreover, the treatment of those patients who develop heart failure with standard medical therapy suggests that the contractile dysfunction is often reversible (T. Suter, unpublished results). Nevertheless, this experience has triggered further research into the molecular mechanisms of anthracycline-induced cardiotoxicity that may lead to strategies for cardioprotection.



View larger version (16K):
[in this window]
[in a new window]
  		Figure 3. Trastuzumab (Herceptin) exacerbates chemotherapy-associated cardiotoxicity. Trastuzumab has antitumor activity against HER2-positive human breast tumor cells in laboratory models and is effective against human HER2-overexpressing breast cancers. In the clinical trials demonstrating the clinical benefit of trastuzumab in patients with metastatic breast cancer, there were an unexpectedly high number of patients who developed cardiac contractile dysfunction and clinically apparent heart failure. [From (28).]

 
Studies in animals and cell culture have provided some insight into the mechanisms for trastuzumab effects on the heart. Gene targeting studies in mice have demonstrated that erbB2, the target of trastuzumab, is essential for cardiac development (30), and conditional deletion of erbB2 in mice leads to the development of a dilated cardiomyopathy (31, 32). Thus, erbB2 is essential for maintenance of normal cardiac structure and function. In vitro studies with cardiac myocytes provide further insights regarding the cellular and molecular mechanisms for trastuzumab effects. erbB2 is expressed in adult cardiac myocytes, along with erbB4, and transmits growth and survival signals in response to the ligand neuregulin-1 (Figure 4Go)(33). In response to anthracyclines, cardiac myocytes show evidence of myofilament degradation (12), as well as cell death by both apoptosis and necrosis (34), and both of these effects are suppressed by neuregulin treatment (35, 36). erbB2 and erbB4 localize in the transverse tubules of ventricular myocytes. Collectively, these data suggest that one role of erbB2/4 signaling is to dynamically regulate sarcomere structure, perhaps in response to stress. In this paradigm, suppression of erbB2 signaling by trastuzumab may accelerate the net breakdown of sarcomeric proteins induced by anthracyclines, increasing the likelihood of cardiac dysfunction and the clinical syndrome of heart failure.



View larger version (40K):
[in this window]
[in a new window]
  		Figure 4. Paracrine signaling between cardiac endothelial cells and ventricular myocytes. A. As illustrated in this section of rat myocardium, ventricular myocytes are surrounded by microvascular endothelial capillaries. Besides supplying blood flow per se, the microvascular endothelial cells provide trophic support to the myocytes, which modulates cardiac structure and function. B. Beyond its role as a "glial growth factor," neuregulin acts also as a paracrine signal between cardiac microvascular endothelial cells and ventricular myocytes. Neuregulin is expressed in the microvascular endothelial cell and protects myocytes from injury in the presence of anthracyclines and other cell stresses. Neuregulin activates erbB2 and erbB4 receptor tyrosine kinases in myocytes, thus regulating several downstream signaling cascades.

 
It is interesting that one of the most sensitive sarcomeric proteins is the giant myofilament protein titin (12). Titin plays a role in sarcomerogenesis, and its breakdown may impair sarcomere turnover (37). Moreover, titin plays a critical role in the regulation of contractile function, serving as an entropic spring imparting both a restoring force to assist in the return of the sarcomere to resting length during diastole, as well as a passive force to assist in the initiation of systole [for review see (38)]. Arguably, any cardiotoxic stress that accelerates the breakdown of titin will lead to a reduction in diastolic function, perhaps before any evidence of cardiac systolic (contractile) dysfunction.


   DESIGNING CARDIOPROTECTIVE STRATEGIES
TOP
 Summary
 Introduction
 Overview of Anthracycline...
 Mechanisms of Anthracycline...
 Designing Cardioprotective...
References
 
The observation that "turning down the volume" on erbB2 signaling with trastuzumab increases the likelihood of anthracycline cardiotoxicity leads to the hypothesis that augmentation of erbB2 signaling prior to or at the time of anthracycline exposure might be cardioprotective; certainly, in vitro studies with recombinant neuregulin support this hypothesis (35, 36). Recent work with the hemizygous neuregulin-1 (knockdown) mouse also supports this hypothesis (39). So, how can we "crank up the volume"?

Pharmacological strategies such as systemic delivery of neuregulin are one possibility, although the pleiotropic growth effects of this ligand, including in some cancers, makes this strategy seem less than optimal. Other pharmacological agents to consider along these lines include growth factors such as insulin-like growth factor-1 (IGF-1), which protect cells against anthracyclines (40). As is the case for neuregulin, however, there are concerns that any such factor may promote cancer growth. Obviously, the ideal strategy would be to locally deploy neuregulin and possibly other cardioprotective ligands in the heart or recruit downstream effector mechanisms. Intriguingly, overexpression of downstream effector kinases like Akt and transcription factors such as GATA4 protect mice from anthracycline cardiotoxicity (41, 42); however, these tools are still far away from clinical utility.

An attractive strategy yet to be explored is to use endogenous ligands and kinases to create a window of cardioprotection. Focusing on neuregulin, for example, we know that there is robust expression of this ligand in the heart, although it appears to have minimal activity at baseline. These levels of expression of neuregulin may well indicate that it serves some physiological function beyond cardiac development. If we knew the physiological mechanisms underlying neuregulin expression and activation in the heart, one could envision a scenario where the induction of neuregulin activity before exposing a patient to anthracycline would create a window of cardioprotection.

Along these lines, we have sought to characterize more fully the endogenous neuregulin expressed in the heart, and understand its mechanisms for activation. Neuregulins come from four known genes: NRG1, NRG2, NRG3, and NRG4. Cardiac neuregulin appears to be primarily a product of NRG1, the best characterized of these genes. The entire human NRG1 gene is 1.4 megabases long (1/2000th of the genome) (43). As a consequence of rich alternative splicing and multiple promoters, at least fifteen different NRG1 isoforms are produced (44). The three structural characteristics we know to differentiate isoforms with respect to in vivo functions and cell biological properties are the type of EGF-like domain ({alpha} or ß), the N-terminal sequence (type I, II, or III), and whether the isoform is initially synthesized as a transmembrane or secretable protein. Cardiac microvascular endothelial cells transcribe at least eleven different NRG1 isoforms, including both {alpha} and ß subtypes (G. Cote and D. Sawyer, unpublished data). All but one of these are predicted to be transmembrane proteins that require proteolytic cleavage for activation.

Gene targeting studies in mice demonstrate that both the EGF and the cytoplasmic domains are required for proper neuregulin function in cardiac development (45). In isolated cells, we have demonstrated that transmembrane neuregulin protein is cleaved in response to oxidative stress and is able to act on cardiac myocytes in a paracrine manner to induce cytoprotection (46). The cleavage of neuregulin under these conditions appears to require the action of a metalloproteinase, and work with recombinant neuregulin constructs has demonstrated a susceptibility of neuregulin to cleavage by ADAM17 and ADAM19 (a disintegrase and metalloproteinase) (47, 48) (Figure 4Go).

Based upon experimental data in skeletal muscle, we hypothesize that physiologic cardiac stress in the form of exercise will increase neuregulin/erbB signaling. In skeletal muscle, neuregulin-1 and the erbB receptors serve a function at the neuromuscular junction to regulate myoblast differentiation as well as formation and maintenance of the post-synaptic endplate (48, 49). We have demonstrated that these proteins are localized in the adult skeletal muscle at the neuromuscular junction in rats (49,50). Moreover, we found that exercise was a potent activator of neuregulin release and subsequent activation of erbB phosphorylation. The proximal mechanisms for neuregulin release during exercise remain incompletely characterized. Interestingly, an exercise-training regimen in people increases the expression of erbB3 receptors in skeletal muscle (51). Increased erbB3 expression may thus increase sensitivity of muscle to neuregulin action. The demonstration that neuregulin increases skeletal muscle glucose uptake (52, 53) suggests the interesting hypothesis that exercise-regulated glucose uptake in skeletal muscle is mediated in part by neuregulin. (Regardless of the mechanisms for neuregulin release and the implications of these findings for glucose homeostasis, these studies have provided intellectual motivation for young neuregulin investigators to find the time to maintain their physical fitness.)

Coming back to the heart and anthracyclines, an attractive hypothesis that arises is that a period of exercise sufficient to activate neuregulin and/or other cardioprotective signaling may protect a cancer patient’s heart during anthracycline exposure. This makes intuitive sense, because periodic exercise is generally associated with cardioprotection and improvements in cardiovascular function (54– 55). This idea is not new, as twenty years ago a group demonstrated that swim training in rats decreased the histopathologic damage induced by anthracyclines (56). As far as we can see from the published literature, however, this concept was never pursued further, and cancer patients undergoing chemotherapy today remain without any clear recommendations with regards to physical activity around the time of treatment.

While we have arrived at this cardioprotective hypothesis via our studies of neuregulin and the insights from trastuzumab, there are many potential mechanisms through which physical activity may ameliorate anthracycline-induced cardiac toxicity. Kanter and colleagues have suggested that exercise training in rats acts to protect via changes in antioxidant activity. Specifically, they reported increased levels of catalase, superoxide dismutase, and glutathione peroxidase in blood, liver, and heart in swim-trained rats, and that this training prevented in part the cardiotoxicity of doxorubicin (56). Other potential mechanisms may involve the beneficial effects of exercise on expression of heat shock proteins (57–59), which are cardioprotective against anthracycline cardiotoxicity (60). Exercise effects on IGF-1 are well-characterized (61, 62), and this growth factor also induces protection from anthracycline exposure (63). Finally, the effects of exercise on adrenergic tone might also promote cardioprotection, based upon the finding that pharmacological administration of the alpha-adrenergic agonist phenylephrine is able to prevent anthracycline cardiotoxicity in mice (43). Two recent studies have confirmed the cardioprotective effect of exercise against doxorubicin toxicity (64, 65).

While the level of evidence for a protective effect of exercise on the heart during anthracycline exposure seems to be growing, concerns about the possible effects of exercise on tumor biology, response to chemotherapy, and patient tolerability remain. Extrapolating from epidemiologic data associating periodic exercise with a lower risk of the development of some forms of cancer, particularly breast and colon (66–69), one can argue that exercise does not promote tumor growth, although animal studies in breast cancer models have given conflicting data. Chemically induced breast cancers are suppressed by voluntary exercise in some settings (70, 71), but show the opposite results in others (72, 73). These conflicting data may be due to the tumor model as well as the form of exercise used in these studies. Regardless, further experimental data in oncogene-driven tumor models more applicable to human cancers should be helpful, as well as studies examining how exercise affects the tumor response to chemotherapy.

Cancer victims appear, in fact, to tolerate a regular physical activity program and report higher quality-of-life scores, suggesting the feasibility of an exercise intervention (74, 75). Unlike recombinant proteins and small-molecule activators of cardioprotective signaling, an exercise intervention comes without intellectual property rights, which of course is a disadvantage, as well as an advantage. Exercise therapy will not make any individual or institution wealthy, and carrying out this work will only get done with public and philanthropic funding to academic investigators. An advantage over patentable drugs, however, is that a proven exercise regimen that improves patient outcome is immediately exportable to all motivated cancer victims throughout the world, at no cost. This combination puts the investigator in the rather unique position of working on a therapy where the risk/benefit ratio is entirely driven by patient outcome, without financial conflicts of interest.


Xuyang Peng, MD, PhD, received her medical training at Hunan Medical School and clinical training in hematology and oncology at the Hunan Tumor Hospital in Hunan, China. Xuyang is currently completing a postdoctoral fellowship at Boston University Medical Center.


Billy Chen is a graduate student in the MD/PhD combined degree program at Boston Uniiversity School of Medicine. Billy’s thesis focuses on furthering our understanding of the mechanisms for anthracycline cardiotoxicity.


Chee Chew Lim, PhD, has a background in bioengineering and completed his graduate work in Physiology at Boston University. Chee is an Assistant Professor of Medicine and studies the turnover of sarcomeric proteins in cardiomyocytes.


Douglas Sawyer, MD, PhD, completed his medical and graduate education at Cornell University and his clinical training in Medicine and Cardiology at Brigham and Women’s Hospital. Doug is currently an Associate Professor of Medicine at Boston University Medical Center and is interested in the mechanisms by which paracrine signaling in the heart regulates cardiac structure and function. Address correspondence to DBS. E-mail Douglas. Sawyer{at}bmc.org; fax 617-414-1719.


   ACKNOWLEDGMENTS
TOP
 Summary
 Introduction
 Overview of Anthracycline...
 Mechanisms of Anthracycline...
 Designing Cardioprotective...
 References
 
DBS is supported by the National Institutes of Health and acknowledges previous support from the American Heart Association, Juvenile Diabetes Research Foundation, Genentech, and Roche. CCL acknowledges funding from the American Heart Association.


   References
TOP
 Summary
 Introduction
 Overview of Anthracycline...
 Mechanisms of Anthracycline...
 Designing Cardioprotective...
 References
 

  1. Gewirtz, D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57, 727–741, (1999).[CrossRef][Medline]
  2. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185–229, (2004). This contemporary review covers in great detail what is known about the mechanisms of anthracycline cytotoxicity. It is an excellent reference for those interested in understanding the chemistry and biological effects of the anthracycline antibiotics.[Abstract/Free Full Text]
  3. Swain, S.M., Whaley, F.S., and Ewer, M.S. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97, 2869–2879, (2003). This retrospective analysis of three trials found that doxorubicin-related congestive heart failure occurs with greater frequency and at a lower cumulative dose than previously reported.[CrossRef][Medline]
  4. Li, T. and Singal, P.K. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol. Circulation 102, 2105–2110, (2000).[Abstract/Free Full Text]
  5. Pacher, P., Liaudet, L., Bai, P. et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicininduced cardiac dysfunction. Circulation 107, 896–904, (2003).[Abstract/Free Full Text]
  6. Mihm, M.J., Yu, F., Weinstein, D.M., Reiser, P.J., and Bauer, J.A. Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: Evidence for selective impairment of myofibrillar creatine kinase. Br. J. Pharmacol. 135, 581–588, (2002).[CrossRef][Medline]
  7. Tokarska-Schlattner, M., Wallimann, T., and Schlattner, U. Multiple interference of anthracyclines with mitochondrial creatine kinases: Preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol. Pharmacol. 61, 516–523, (2002).[Abstract/Free Full Text]
  8. Olson, R.D. and Mushlin, P.S. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J. 4, 3076–3086, (1990).[Abstract]
  9. Ito, H., Miller, S.C., Billingham, M.E. et al. M. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc. Natl. Acad. Sci. 87, 4275–4279, (1990).[Abstract/Free Full Text]
  10. Jeyaseelan, R., Poizat, C., Baker, R.K., Abdishoo, S., Isterabadi, L. B., Lyons, G.E., and Kedes, L. A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. J. Biol. Chem. 272, 22800–22808, (1997).[Abstract/Free Full Text]
  11. Jeyaseelan, R., Poizat, C., Wu, H.Y., and Kedes, L. Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J. Biol. Chem. 272, 5828–5832, (1997).[Abstract/Free Full Text]
  12. Lim, C.C., Zuppinger, C., Guo, X., Kuster, G.M., Helmes, M., Eppenberger, H.M., Suter, T.M., Liao, R., and Sawyer, D.B. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J. Biol. Chem. 279, 8290–8299, (2004).[Abstract/Free Full Text]
  13. Fu, M., Matoba, M., Liang, Q.M., Sjogren, K.G., and Hjalmarson, A. Properties of G protein–modulated receptor-adenylyl cyclase system in myocardium of spontaneously hypertensive rats treated with adriamycin. Int. J. Cardiol. 44, 9–18, (1994).[CrossRef][Medline]
  14. Calderone, A., de Champlain, J., and Rouleau, J.L. Adriamycin-induced changes to the myocardial beta-adrenergic system in the rabbit. J. Mol. Cell Cardiol. 23, 333–342, (1991).[CrossRef][Medline]
  15. Singal, P.K. and Iliskovic, N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339, 900–905, (1998).[Free Full Text]
  16. Takahashi, S., Denvir, M.A., Harder, L., Miller, D.J., Cobbe, S.M., Kawakami, M., MacFarlane, N.G., and Okabe, E. Effects of in vitro and in vivo exposure to doxorubicin (adriamycin) on caffeine-induced Ca2+ release from sarcoplasmic reticulum and contractile protein function in "chemically-skinned" rabbit ventricular trabeculae. Jpn. J. Pharmacol. 76, 405–413, (1998).[CrossRef][Medline]
  17. Legha, S.S., Benjamin, R.S., Mackay, B., Ewer, M., Wallace, S., Valdivieso, M., Rasmussen, S.L., Blumenschein, G.R., and Freireich, E.J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med. 96, 133–139, (1982).
  18. Unverferth, D.V., Mehegan, J.P., Nelson, R.W., Scott, C.C., Leier, C.V., and Hamlin, R.L. The efficacy of N-acetylcysteine in preventing doxorubicin-induced cardiomyopathy in dogs. Semin. Oncol. 10, 2–6, (1983).
  19. Myers, C., Bonow, R., Palmeri, S., Jenkins, J., Corden, B., Locker, G., Doroshow, J., and Epstein, S. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. 10, 53–55, (1983).[Medline]
  20. Swain, S.M., Whaley, F.S., Gerber, M.C. et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 15, 1318–1332, (1997).[Abstract/Free Full Text]
  21. Swain, S.M. and Vici, P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: Expert panel review. J. Cancer Res. Clin. Oncol. 130, 1–7, (2004).[CrossRef][Medline]
  22. Hensley, J.L., Schuchter, L.M., Lindley, C. et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J. Clin. Oncol. 17, 3333–3355 (1999).[Abstract/Free Full Text]
  23. Klapper, L.N., Kirschbaum, M.H., Sela, M., and Yarden, Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77, 25–79, (2000).[Medline]
  24. Borg, A., Baldetorp, B., Ferno, M., Killander, D., Olsson, H., and Sigurdsson, H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6, 137–143, (1991).[Medline]
  25. Fendly, B.M., Kotts, C., Vetterlein, D. et al. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J. Biol. Response Mod. 9, 449–455, (1990).[Medline]
  26. Carter, P., Presta, L., Gorman, C.M. et al. Humanization of an antip185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. 89, 4285–4289, (1992).[Abstract/Free Full Text]
  27. Slamon, D. and Pegram, M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin. Oncol. 28, 13–19, (2001).
  28. Slamon, D.J., Leyland-Jones, B., Shak, S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792, (2001). This paper was the first to demonstrate the clinical benefits of HER2-targeted therapy in patients with metastatic breast cancer. Also presented in this report is the finding that HER2-targeted therapy appeared to increase the risk of heart failure when given with anthracyclines. In spite of this adverse effect, the overall benefit of trastuzumab on patient mortality was clear and led to FDA approval of this therapy, with a warning against using it concurrently with anthracyclines.[Abstract/Free Full Text]
  29. Feldman, A.M., Lorell, B.H., and Reis, S.E. Trastuzumab in the treatment of metastatic breast cancer: Anticancer therapy versus cardiotoxicity. Circulation 102, 272–274, (2000).[Abstract/Free Full Text]
  30. Lee, K.F., Simon, H., Chen, H., Bates, B., Hung, M.C., and Hauser, C. Requirement for neuregulin receptor Erbb2 in neural and cardiac development. Nature 378, 394–398, (1995).[CrossRef][Medline]
  31. Crone, S.A., Zhao, Y.Y., Fan, L. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8, 459–465, (2002). This and reference 32 were important studies in establishing the essential role of erbB2 in the post-natal heart. The investigators created a cardiac specific erbB2 knockout mouse that had normal cardiac development but after birth acquired a progressive cardiomyopathy.[CrossRef][Medline]
  32. Ozcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hubner, N., Chien, K. R., Birchmeier, C., and Garratt, A.N. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. 99, 8880–8885, (2002).[Abstract/Free Full Text]
  33. Zhao, Y.Y., Sawyer, D.R., Baliga, R.R., Opel, D.J., Han, X., Marchionni, M.A., and Kelly, R.A. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J. Biol. Chem. 273, 10261–10269, (1998).[Abstract/Free Full Text]
  34. Sawyer, D.B., Fukazawa, R., Arstall, M.A., and Kelly, R.A. Daunorubicininduced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ. Res. 84, 257–265, (1999).[Abstract/Free Full Text]
  35. Sawyer, D.B., Zuppinger, C., Miller, T.A., Eppenberger, H.M., and Suter, T.M. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: Potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105, 1551–1554, (2002).[Abstract/Free Full Text]
  36. Fukazawa, R., Miller, T.A., Kuramochi, Y., Frantz, S., Kim, Y.D., Marchionni, M.A., Kelly, R.A., and Sawyer, D.B. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J. Mol. Cell Cardiol. 35, 1473– 1479, (2003).[CrossRef][Medline]
  37. Person, V., Kostin, S., Suzuki, K., Labeit, S., and Schaper, J. Antisense oligonucleotide experiments elucidate the essential role of titin in sarcomerogenesis in adult rat cardiomyocytes in long-term culture. J. Cell Sci. 113 Pt 21, 3851–3859, (2000).[Abstract]
  38. Granzier, H.L. and Labeit, S. The giant protein titin: A major player in myocardial mechanics, signaling, and disease. Circ. Res. 94, 284–295, (2004).[Abstract/Free Full Text]
  39. Liu, F.F., Stone, J.R., Schuldt, A.J. et al. Heterozygous knockout of the neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. Am. J. Physiol Heart Circ. Physiol. (2005).
  40. Kunisada, K., Negoro, S., Tone, E., Funamoto, M., Osugi, T., Yamada, S., Okabe, M., Kishimoto, T., and Yamauchi-Takihara, K. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc. Natl. Acad. Sci. 97, 315–319, (2000).[Abstract/Free Full Text]
  41. Taniyama, Y. and Walsh, K. Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. J. Mol. Cell Cardiol. 34, 1241–1247, (2002).[CrossRef][Medline]
  42. Aries, A., Paradis, P., Lefebvre, C., Schwartz, R.J., and Nemer, M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc. Natl. Acad. Sci. 101, 6975–6980, (2004). This study demonstrated that the overexpression of the transcription factor GATA-4, known to be important in the regulation of cardiac sarcomeric protein expression, protects the heart against anthracycline toxicity.[Abstract/Free Full Text]
  43. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V. et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71, 877–892, (2002).[CrossRef][Medline]
  44. Gerecke, K.M., Wyss, J.M., Karavanova, I., Buonanno, A., and Carroll, S. L. ErbB transmembrane tyrosine kinase receptors are differentially expressed throughout the adult rat central nervous system. J. Comp. Neurol. 433, 86–100, (2001).[CrossRef][Medline]
  45. Gassanov, N., Er, F., Zagidullin, N., and Hoppe, U.C. Endothelin induces differentiation of ANP-EGFP expressing embryonic stem cells towards a pacemaker phenotype. FASEB J. 18, 1710–1712, (2004).[Abstract/Free Full Text]
  46. Kuramochi, Y., Cote, G.M., Guo, X., Lebrasseur, N.K., Cui, L., Liao, R., and Sawyer, D.B. Cardiac endothelial cells regulate reactive oxygen species- induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J. Biol. Chem. 279, 51141–51147, (2004). In this paper we established the neuregulin-1ß/erbB4 signaling system as a paracrine mechanism by which CMECs modulate cardiomyocyte survial and suggested that this system is involved in cardiac adaptiation to oxidative stress.[Abstract/Free Full Text]
  47. Shirakabe, K., Wakatsuki, S., Kurisaki, T., and Fujisawa-Sehara, A. Roles of Meltrin beta /ADAM19 in the processing of neuregulin. J. Biol. Chem. 276, 9352–9358, (2001).[Abstract/Free Full Text]
  48. Montero, J.C., Yuste, L., Diaz-Rodriguez, E., Esparis-Ogando, A., and Pandiella, A. Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. Mol. Cell Neurosci. 16, 631–648, (2000).[CrossRef][Medline]
  49. Sanes, J.R. and Lichtman, J.W. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat. Rev. Neurosci. 2, 791– 805, (2001).[Medline]
  50. Lebrasseur, N.K., Cote, G.M., Miller, T.A., Fielding, R.A., and Sawyer, D.B. Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. Am. J. Physiol. Cell Physiol. 284, C1149–C1155, (2003).[Abstract/Free Full Text]
  51. Lebrasseur N.K., Mizer K.C., Parkington J.D., Sawyer D.B., and Fielding R.A. The expression of neuregulin and erbB receptors in human skeletal muscle: Effects of progressive resistance training. Eur. J. Appl. Physiol. [Epub ahead of print] (2005).
  52. Canto, C., Suarez, E., Lizcano, J.M. et al. Neuregulin signaling on glucose transport in muscle cells. J. Biol.Chem. 279, 12260–12268, (2004).[Abstract/Free Full Text]
  53. Suarez, E., Bach, D., Cadefau, J., Palacin, M., Zorzano, A., and Guma, A. A novel role of neuregulin in skeletal muscle. Neuregulin stimulates glucose uptake, glucose transporter translocation, and transporter expression in muscle cells. J. Biol. Chem. 276, 18257–18264, (2001).[Abstract/Free Full Text]
  54. Chandrashekhar, Y. and Anand, I.S. Exercise as a coronary protective factor. Am. Heart J. 122, 1723–1739, (1991).[CrossRef][Medline]
  55. Kavanagh, T. Exercise and the heart. Ann. Acad. Med. Singapore 12, 331–337, (1983).
  56. Kanter, M.M., Hamlin, R.L., Unverferth, D.V., Davis, H.W., and Merola, A. J. Effect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin. J. Appl. Physiol. 59, 1298–1303, (1985). This was the first study to show that exercise-trained rodents were protected from anthracycline cardiotoxicity. Although twenty years have passed since this publication, the mechanism of the exercise protection in the heart is still unknown, and the potential benefits of exercise during cancer treatment have not been explored.[Abstract/Free Full Text]
  57. Harris, M.B. and Starnes, J.W. Effects of body temperature during exercise training on myocardial adaptations. Am. J. Physiol. Heart Circ. Physiol. 280, H2271–H2280, (2001).[Abstract/Free Full Text]
  58. Noble, E.G., Moraska, A., Mazzeo, R.S., Roth, D.A., Olsson, M.C., Moore, R.L., and Fleshner, M. Differential expression of stress proteins in rat myocardium after free wheel or treadmill run training. J. Appl. Physiol. 86, 1696–1701, (1999).[Abstract/Free Full Text]
  59. Powers, S.K., Lennon, S.L., Quindry, J., and Mehta, J.L. Exercise and cardioprotection. Curr. Opin. Cardiol. 17, 495–502, (2002).[CrossRef][Medline]
  60. Ito, H., Shimojo, T., Fujisaki, H., Tamamori, M., Ishiyama, S., Adachi, S., Abe, S., Marumo, F., and Hiroe, M. Thermal preconditioning protects rat cardiac muscle cells from doxorubicin-induced apoptosis. Life Sci. 64, 755–761, (1999).[CrossRef][Medline]
  61. Colao, A., Vitale, G., Pivonello, R., Ciccarelli, A., Di Somma, C., and Lombardi, G. The heart: an end-organ of GH action. Eur.J Endocrinol. 151 Suppl 1, S93–101, (2004).[Abstract]
  62. Schulze, P.C., Gielen, S., Schuler, G., and Hambrecht, R. Chronic heart failure and skeletal muscle catabolism: Effects of exercise training. Int. J Cardiol. 85, 141–149, (2002).[CrossRef][Medline]
  63. Carro, E., Trejo, J.L., Busiguina, S., and Torres-Aleman, I. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J. Neurosci. 21, 5678–5684, (2001).[Abstract/Free Full Text]
  64. Chicco, A.J., Schneider, C.M., and Hayward, R. Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005). This study showed that the hearts of rats allowed to exercise spontaneously, by providing access to an exercise wheel for eight weeks, were protected against the acute effects of the anthracycline doxorubicin. It is an important study as it demonstrates that exerciseinduced cardioprotection comes from low-intensity increases in physical activity.
  65. Ascensao, A., Magalhaes, J., Soares, J., Ferreira, R., Neuparth, M., Marques, F., Oliveira, J., and Duarte, J. Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice. Int. J. Cardiol. 100, 451–460, (2005).[CrossRef][Medline]
  66. Frisch, R.E., Wyshak, G., Albright, N.L. et al. Lower prevalence of breast cancer and cancers of the reproductive system among former college athletes compared to non-athletes. Br. J. Cancer 52, 885–891, (1985).[Medline]
  67. Wyshak, G., Frisch, R.E., Albright, N.L., Albright, T.E., and Schiff, I. Lower prevalence of benign diseases of the breast and benign tumours of the reproductive system among former college athletes compared to non-athletes. Br. J Cancer 54, 841–845, (1986).[Medline]
  68. Barnard, R.J. Prevention of cancer through lifestyle changes. Evid. Based. Complement. Alternat. Med. 1, 233–239, (2004).[Abstract/Free Full Text]
  69. Gotay, C.C. Behavior and cancer prevention. J Clin.Oncol. 23, 301–310, 2005.[Abstract/Free Full Text]
  70. Cohen, L.A., Kendall, M.E., Meschter, C., Epstein, M.A., Reinhardt, J., and Zang, E. Inhibition of rat mammary tumorigenesis by voluntary exercise. In Vivo 7, 151–158, (1993).[Medline]
  71. Simopoulos, A.P. Nutritional cancer risks derived from energy and fat.Med. Oncol. Tumor Pharmacother. 4, 227–239, (1987).[Medline]
  72. Thompson, H.J., Westerlind, K.C., Snedden, J., Briggs, S., and Singh, M. Exercise intensity dependent inhibition of 1-methyl-1-nitrosourea induced mammary carcinogenesis in female F-344 rats. Carcinogenesis 16, 1783–1786, (1995).[Abstract/Free Full Text]
  73. Thompson, H.J., Westerlind, K.C., Snedden, J.R., Briggs, S., and Singh, M. Inhibition of mammary carcinogenesis by treadmill exercise. J. Natl. Cancer Inst. 87, 453–455, (1995).[Free Full Text]
  74. Kolden, G.G., Strauman, T.J., Ward, A. et al. A pilot study of group exercise training (GET) for women with primary breast cancer: feasibility and health benefits. Psychooncology 11, 447–456, (2002). This paper demonstrated that exercise training for women with primary breast cancer was feasible, safe, and well-tolerated and highlighted the need for inclusion of physical activity programs in comprehensive, complementary treatment regimes for breast cancer patients.[CrossRef][Medline]
  75. McTiernan, A., Schwartz, R.S., Potter, J., and Bowen, D. Exercise clinical trials in cancer prevention research: A call to action. Cancer Epidemiol. Biomarkers Prev. 8, 201–207, (1999). This paper describes the potential utility of the randomized clinical trial design in providing answers about bias, mechanisms, behavior change, and dose response in defining the causal pathway between physical activity and cancer. The authors recommend that a series of small clinical trials of exercise interventions be conducted to measure exercise effects on biomarkers for cancer risk, to learn about exercise behavior change in individuals at risk for cancer, and to serve as feasibility studies for larger randomized controlled trials of cancer and precursor end points and for community intervention studies.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Integr Cancer TherHome page
K. Y. Wonders and B. S. Reigle
Trastuzumab and Doxorubicin-Related Cardiotoxicity and the Cardioprotective Role of Exercise
Integr Cancer Ther, March 1, 2009; 8(1): 17 - 21.
[Abstract] [PDF]

Home page
 Mol Cancer ResHome page
G. Hua, B. Zhu, F. Rosa, N. Deblon, J. Adelaide, B. Kahn-Perles, D. Birnbaum, and J. Imbert
A Negative Feedback Regulatory Loop Associates the Tyrosine Kinase Receptor ERBB2 and the Transcription Factor GATA4 in Breast Cancer Cells
Mol. Cancer Res., March 1, 2009; 7(3): 402 - 414.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. D. Venkatakrishnan, K. Dunsmore, H. Wong, S. Roy, C. K. Sen, A. Wani, J. L. Zweier, and G. Ilangovan
HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest
Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1736 - H1744.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Li, Q. Pan, W. Han, Z. Liu, L. Li, and X. Hu
Schisandrin B Prevents Doxorubicin-Induced Cardiotoxicity via Enhancing Glutathione Redox Cycling
Clin. Cancer Res., November 15, 2007; 13(22): 6753 - 6760.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. Belardinelli
Exercise Training in Chronic Heart Failure: How to Harmonize Oxidative Stress, Sympathetic Outflow, and Angiotensin II
Circulation, June 19, 2007; 115(24): 3042 - 3044.
[Full Text] [PDF]

This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peng, X.
Right arrow Articles by Sawyer, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peng, X.
Right arrow Articles by Sawyer, D. B.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.